Trial Profile
Phase Ib Dose-confirmation Study of ASLAN001 Combined With Weekly Paclitaxel and Carboplatin in Advanced Solid Tumours, Followed by an Open-label Phase II Study in Patients With Stage I-III HER2 Positive Breast Cancer
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 28 Feb 2022
Price :
$35
*
At a glance
- Drugs Varlitinib (Primary) ; Carboplatin; Paclitaxel; Trastuzumab
- Indications Advanced breast cancer; Early breast cancer; HER2 positive breast cancer; Male breast cancer; Solid tumours
- Focus Therapeutic Use
- 23 Feb 2022 Results (n=37) from phase 1b of the study published in the Targeted Oncology
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology
- 17 May 2018 According to an ASLAN Pharmaceuticals media release, new data from phase 1b part of this study will be presented at the upcoming 2018 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, Illinois, 1-5 June 2018.